Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies[J]. N Engl J Med, 2000, 342(5): 301-307．
[2]
Imagawa A, Hanafusa T, UchigataY, et al. Fuminant type 1 diabetes: A nationwide survey in Japan[J]. Diabetes Care, 2003, 26(8): 2345-2352．
[3]
Cho YM, Kim JT, Ko KS, et al. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type1 diabetes[J]. Diabetologia, 2007, 50(11): 2276-2279.
Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners[J]. Nat Clin Pract Endocrinol Metab, 2007, 3(1): 36-45.
[6]
Huang Z, Xu L, Li F, et al. Fulminant type 1 diabetes mellitus with rhabdomyolysis: Have we overlooked the situation?[J]. Diabetes Res Clin Pract, 2010, 90(3): e47-e49
Imagawa A, Hanafusa T, Uehigata Y, el al. Different contribution of class Ⅱ HLA in fulminant and typical auloimmune type l diabetes mellitus[J]. Diabetologia, 2005, 48(2): 294-300.
[12]
Tanaka S, Nishida Y, Aida K, et al. Enterovirus infection, CXC chemokine ligand 10(CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes[J]. Diabetes, 2009, 58(10): 2285-2291.
[13]
Akatsuka H, Yano Y, Gabazza EC, et al. A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody[J]. Diabetes Res Clin Pract, 2009, 84(3): e50-e52.
